http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107840846-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 2017-08-21^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107840846-B |
| titleOfInvention | Pyrimidine ring-containing compound, EGFR inhibitor and application thereof |
| abstract | The invention relates to a pyrimidine ring-containing compound, an EGFR inhibitor and application thereof, and belongs to the technical field of medicines. The pyrimidine ring-containing compound comprises a compound shown as a formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The EGFR inhibitors include the pyrimidine ring-containing compounds described above. The compound can inhibit activation or resistance mutation of one or more EGFR, can be used for preparing medicaments for regulating the activity of EGFR tyrosine kinase or treating EGFR related diseases, such as cancers, diabetes, immune system diseases, neurodegenerative diseases or cardiovascular diseases and the like, and is particularly suitable for preparing medicaments for treating non-small cell lung cancer caused by EGFR mutation, including sensitive mutation (such as L858R mutation or exon19 deletion) and drug-resistant mutation (such as EGFR T790M mutation). |
| priorityDate | 2016-09-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 170 of 170.